Crescendo Equity Partners
VC Fund
Seoul, South Korea
Crescendo Equity Partners is a VC fund in Seoul focused on Blockchain and Electronics. A specialized private equity investment firm.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Crescendo Equity Partners invests in
Stages Crescendo Equity Partners invests in
Countries Crescendo Equity Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Park Seong-min
|
|||
Investment Focus
Industry
- Blockchain 4 (29%)
- Electronics 2 (14%)
- Information Technology 2 (14%)
- Apps 1 (7%)
- SaaS 1 (7%)
Stage
- Private Equity 6 (43%)
- Venture - Series Unknown 3 (21%)
- Initial Coin Offering 2 (14%)
- Seed 1 (7%)
- Post-IPO Debt 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Park Seong-min
Vice President
|
Vice President | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Medipost
|
MEDIPOST’s mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine.MEDIPOST has been making resilient efforts despite difficulties and challenges in the field of stem cell research and commercialization, while upholding strong corporate ethics and values. Today, MEDIPOST isthe global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012. | $140M / Post-IPO Equity / Jan 09, 2026 | |
|
Medipost
|
MEDIPOST’s mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine.MEDIPOST has been making resilient efforts despite difficulties and challenges in the field of stem cell research and commercialization, while upholding strong corporate ethics and values. Today, MEDIPOST isthe global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012. | $138.9M / Post-IPO Debt / Dec 18, 2025 | |
Cyberdigm
|
Cyberdigm is a service provider involved in document centralization, collaboration and knowledge management. | $73.4M / Private Equity / May 08, 2024 | |
Flexcil
|
Flexcil originally started because our team thought carrying books around was a hassle. Textbooks are big and heavy, and you have to switch them for each class. Then losing a book or a notebook entails losing all the data that you’ve organized on them. The purpose and dream of Flexcil is to lighten the bags of students around the world by replacingthick and heavy paper texts with light, digital text-books. Technology has been improved extremely, but how to study has not caught up. With Flexcil, studying becomes enjoyable and easier. We want to innovate the study environment and digital study experience by providing the best convenient digital study tool. | $37.7M / Private Equity / Feb 22, 2024 | |
Beaver Works
|
Beaver Works is a retail software company providing SaaS solutions such as POS systems, self-order kiosks, payment processing, and store management tools. It helps offline retailers streamline operations, manage sales data, and improve customer transactions through integrated digital systems designed to support efficient store operations andbusiness automation. | Venture - Series Unknown / Feb 22, 2024 | |
Line Next
|
Line Next is committed to advancing and expanding the worldwide NFT industry. LINE NEXT seeks to offer innovative digital experiences and pave the road for the future by utilising blockchain and NFT technology. | $140M / Private Equity / Dec 12, 2023 | |
Intimax
|
Intimax specializes in semiconductor and electronic equipment design and manufacturing. The company's products include wafer laminators, wafer mounted, wafer saw machines, ultraviolet irradiation, and a pin insert system. | Venture - Series Unknown / Jan 01, 2023 | |
Cardio Health
|
CardioHealth is developing a service that utilizes the Cardio AI agent to perform basic cardiac stress tests for individuals at home or in the gym, enabling early detection of cardiovascular diseases. Currently, we are leveraging a VR exercise bike platform to increase engagement in various non-patient exercises, thereby collecting a large volumeof cardiac stress test data to train the AI. | $1M / Seed / Jun 08, 2022 | |
|
Medipost
|
MEDIPOST’s mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine.MEDIPOST has been making resilient efforts despite difficulties and challenges in the field of stem cell research and commercialization, while upholding strong corporate ethics and values. Today, MEDIPOST isthe global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012. | $115.6M / Private Equity / Mar 17, 2022 | |
Alpha Plus
|
Alpha Plus specializes in the development of vacuum components and equipment based on high and ultra-high vacuum technology. The company's main business areas are vacuum components and vacuum deposition equipment. Based on accumulated technology and know-how that has been researched, developed, and commercialized over the years, the companyhas succeeded in localizing vacuum components for mass production. | Venture - Series Unknown / Jan 01, 2022 | |
| See all 14 investments → | |||
Co-Investors
IDG Capital
2 deals together
Sky Lake Investment
2 deals together
Translink Capital
2 deals together
KyungDong Invest
1 deal together
Ledger Capital
1 deal together
Nanuhm Angels
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Crescendo Equity Partners invest in?
Crescendo Equity Partners invests primarily in Blockchain, Electronics and Information Technology startups, most often at Private Equity and Venture - Series Unknown stage. Most of the 14 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Crescendo Equity Partners?
Public channels for Crescendo Equity Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Crescendo Equity Partners?
The team at Crescendo Equity Partners includes Park Seong-min (Vice President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
